EP4735581A2 - Procédés de fabrication et d'utilisation de cellules immunitaires modifiées - Google Patents

Procédés de fabrication et d'utilisation de cellules immunitaires modifiées

Info

Publication number
EP4735581A2
EP4735581A2 EP24833045.8A EP24833045A EP4735581A2 EP 4735581 A2 EP4735581 A2 EP 4735581A2 EP 24833045 A EP24833045 A EP 24833045A EP 4735581 A2 EP4735581 A2 EP 4735581A2
Authority
EP
European Patent Office
Prior art keywords
cell
cells
protein
cancer
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24833045.8A
Other languages
German (de)
English (en)
Inventor
Christopher S. SEET
Suwen LI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California San Diego UCSD
Original Assignee
University of California
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California San Diego UCSD filed Critical University of California
Publication of EP4735581A2 publication Critical patent/EP4735581A2/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne une cellule comprenant une modification d'inactivation dans le gène FAS et/ou FASL; la cellule n'exprimant pas de protéine FAS et/ou FASL fonctionnelle. L'invention concerne également un procédé de fabrication d'une cellule, le procédé comprenant la culture d'une cellule selon l'invention dans des conditions appropriées pour permettre la différenciation in vitro de la cellule en une cellule mature. L'invention concerne également des cellules produites par les procédés de l'invention ainsi qu'un procédé de traitement d'un sujet comprenant l'administration de cellules selon l'invention.
EP24833045.8A 2023-06-30 2024-06-28 Procédés de fabrication et d'utilisation de cellules immunitaires modifiées Pending EP4735581A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363524313P 2023-06-30 2023-06-30
PCT/US2024/036123 WO2025006959A2 (fr) 2023-06-30 2024-06-28 Procédés de fabrication et d'utilisation de cellules immunitaires modifiées

Publications (1)

Publication Number Publication Date
EP4735581A2 true EP4735581A2 (fr) 2026-05-06

Family

ID=93940009

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24833045.8A Pending EP4735581A2 (fr) 2023-06-30 2024-06-28 Procédés de fabrication et d'utilisation de cellules immunitaires modifiées

Country Status (2)

Country Link
EP (1) EP4735581A2 (fr)
WO (1) WO2025006959A2 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4188395A1 (fr) * 2020-07-30 2023-06-07 Institut Curie Cellules immunitaires défectives en socs1

Also Published As

Publication number Publication date
WO2025006959A3 (fr) 2025-04-03
WO2025006959A2 (fr) 2025-01-02

Similar Documents

Publication Publication Date Title
AU2023202195B2 (en) Methods of generating T-cells from stem cells and immunotherapeutic methods using the T-cells
AU2020291457B2 (en) Engineered off-the-shelf immune cells and methods of use thereof
US20210123022A1 (en) Stem cell-engineered inkt cell-based off-the-shelf cellular therapy
US20220289814A1 (en) Engineered t cells and methods of producing thereof
WO2023168341A1 (fr) Cellules modifiées et méthodes d'utilisation
EP4735581A2 (fr) Procédés de fabrication et d'utilisation de cellules immunitaires modifiées
WO2024102707A1 (fr) Procédés et compositions pour générer des cellules immunitaires à partir de cellules progénitrices
WO2023224923A2 (fr) Cellules modifiées et méthodes d'utilisation
WO2025208050A2 (fr) Lymphocytes t invariants associés aux muqueuses (mait) modifiés et leurs procédés de fabrication et d'utilisation
WO2024173937A1 (fr) Cellules immunitaires modifiées par des cellules souches pluripotentes pour thérapie cellulaire standard

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE